Mp46-13 Transperineal Targeted Microwave Ablation (Tma) With 3d Ultrasound-Guidance for Treating Benign Prostatic Hyperplasia: A Safety and Feasibility Study (Betty)

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology III (MP46)1 May 2024MP46-13 TRANSPERINEAL TARGETED MICROWAVE ABLATION (TMA) WITH 3D ULTRASOUND-GUIDANCE FOR TREATING BENIGN PROSTATIC HYPERPLASIA: A SAFETY AND FEASIBILITY STUDY (BETTY) Peter Ka-Fung Chiu, Ka-Lun Lo, Chi-Hang Yee, Jeremy Yuen-Chun Teoh, Ho Fai Wong, Angel W. Y. Kong, and Chi-Fai Ng Peter Ka-Fung ChiuPeter Ka-Fung Chiu , Ka-Lun LoKa-Lun Lo , Chi-Hang YeeChi-Hang Yee , Jeremy Yuen-Chun TeohJeremy Yuen-Chun Teoh , Ho Fai WongHo Fai Wong , Angel W. Y. KongAngel W. Y. Kong , and Chi-Fai NgChi-Fai Ng View All Author Informationhttps://doi.org/10.1097/01.JU.0001008668.53858.38.13AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: This trial aims to investigate the safety and feasibility of 3D ultrasound-guided transperineal targeted microwave ablation(TMA) to treat benign prostatic hyperplasia(BPH). METHODS: This is a pilot study (NCT05443451) on 3D Ultrasound-Guided Transperineal Targeted Microwave ablation (TMA) for 12 men with BPH. This is a prospective, single centre, and non-comparative trial, including men with IPSS≥14, prostate size 30-80ml, Qmax<15ml/s, and post-void residual urine <150ml. Exclusion criteria included significant intravesical median lobe, prior prostate surgery, history of prostate cancer, history of bladder or urethral pathology, and contraindication for contrast MRI scan. The TMA procedure was performed under general or spinal anaesthesia, or local anaesthesia with IV sedation. The TATO3 microwave generator and needles were used for ablation. TMA needles were inserted transperineally via Minigrid or full grid, under guidance of Koelis Trinity 3D transrectal ultrasound (TRUS) probe with organ-based tracking (OBT) technology to accurately track needle positions. Sequential needle ablations of 1-3 treatments per lobe were performed. Foley's catheter was removed at 1 week. Patients were followed up to 6 months. The primary outcome of adverse effects based on Clavien Dindo classification within 6 months. A per-protocol MRI prostate was performed at 1 week and 6 months, and TRUS prostate sizing at 3 and 6 months. Symptom scores including IPSS, QOL, IIEF-5, MSHQ-EjD-SF, and EQ-5D-5L scores were taken at baseline, 1-month, 3-month and 6-month. RESULTS: TMA was successfully performed for all 12 patients in the trial. The median number of TMA ablations was 4 (IQR 2.5-4) and ablation time and operation time was 20 and 44 minutes, respectively. For the primary outcome, there were only grade 1-2 adverse events(AE), including failure to wean off catheter on day 7 and required 10-12 days of Foley's catheter (n=3, grade 2), hematuria (n=3, grade 1), and frequent bowel opening requiring anti-diarrheal drug (n=1, grade 2). The parameters at baseline and at different timepoints are shown in Table 1. CONCLUSIONS: In this first pilot study, transperineal TMA guided by 3D Ultrasound and organ-based tracking was shown to be safe and effective in men with symptomatic BPH. Source of Funding: Nil © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e758 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Peter Ka-Fung Chiu More articles by this author Ka-Lun Lo More articles by this author Chi-Hang Yee More articles by this author Jeremy Yuen-Chun Teoh More articles by this author Ho Fai Wong More articles by this author Angel W. Y. Kong More articles by this author Chi-Fai Ng More articles by this author Expand All Advertisement PDF downloadLoading ...